Literature DB >> 10773783

Genotype and phenotype in cystic fibrosis.

J Zielenski1.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene which encodes a protein expressed in the apical membrane of exocrine epithelial cells. CFTR functions principally as a cAMP-induced chloride channel and appears capable of regulating other ion channels. Besides the most common mutation, DeltaF508, accounting for about 70% of CF chromosomes worldwide, more than 850 mutant alleles have been reported to the CF Genetic Analysis Consortium. These mutations affect CFTR through a variety of molecular mechanisms which can produce little or no functional CFTR at the apical membrane. This genotypic variation provides a rationale for phenotypic effects of the specific mutations. The extent to which various CFTR alleles contribute to clinical variation in CF is evaluated by genotype-phenotype studies. These demonstrated that the degree of correlation between CFTR genotype and CF phenotype varies between its clinical components and is highest for the pancreatic status and lowest for pulmonary disease. The poor correlation between CFTR genotype and severity of lung disease strongly suggests an influence of environmental and secondary genetic factors (CF modifiers). Several candidate genes related to innate and adaptive immune response have been implicated as pulmonary CF modifiers. In addition, the presence of a genetic CF modifier for meconium ileus has been demonstrated on human chromosome 19q13.2. The phenotypic spectrum associated with mutations in the CFTR gene extends beyond the classically defined CF. Besides patients with atypical CF, there are large numbers of so-called monosymptomatic diseases such as various forms of obstructive azoospermia, idiopathic pancreatitis or disseminated bronchiectasis associated with CFTR mutations uncharacteristic for CF. The composition, frequency and type of CFTR mutations/variants parallel the spectrum of CFTR-associated phenotypes, from classic CF to mild monosymptomatic presentations. Expansion of the spectrum of disease associated with the CFTR mutant genes creates a need for revision of the diagnostic criteria for CF and a dilemma for setting nosologic boundaries between CF and other diseases with CFTR etiology. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773783     DOI: 10.1159/000029497

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  101 in total

Review 1.  Value of genetic testing in the management of pancreatitis.

Authors:  D C Whitcomb
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

2.  Diagnostic testing by CFTR gene mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum.

Authors:  Iris Schrijver; Sudha Ramalingam; Ramalingam Sankaran; Steve Swanson; Charles L M Dunlop; Steven Keiles; Richard B Moss; John Oehlert; Phyllis Gardner; E Robert Wassman; Anja Kammesheidt
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

Review 3.  Patterns of GI disease in adulthood associated with mutations in the CFTR gene.

Authors:  Michael Wilschanski; Peter R Durie
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

4.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

5.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

6.  Modifier variant of METTL13 suppresses human GAB1-associated profound deafness.

Authors:  Rizwan Yousaf; Zubair M Ahmed; Arnaud Pj Giese; Robert J Morell; Ayala Lagziel; Alain Dabdoub; Edward R Wilcox; Sheikh Riazuddin; Thomas B Friedman; Saima Riazuddin
Journal:  J Clin Invest       Date:  2018-03-12       Impact factor: 14.808

Review 7.  Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis.

Authors:  Aleksandra Nikolic
Journal:  Lung       Date:  2018-05-12       Impact factor: 2.584

Review 8.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

9.  Clinical and molecular characterization of S1118F-CFTR.

Authors:  Himabindu Penmatsa; Carla A Frederick; Sunitha Nekkalapu; Veronica G Conoley; Weiqiang Zhang; Chunying Li; John Kappes; Dennis C Stokes; Anjaparavanda P Naren
Journal:  Pediatr Pulmonol       Date:  2009-10

10.  Mapping of genetic modifiers of Nr2e3 rd7/rd7 that suppress retinal degeneration and restore blue cone cells to normal quantity.

Authors:  Neena B Haider; Weidong Zhang; Ron Hurd; Akihiro Ikeda; Arne M Nystuen; Jürgen K Naggert; Patsy M Nishina
Journal:  Mamm Genome       Date:  2008-02-20       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.